Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7487-7492

  Greig, Iain R ^a   Idris, Aymen I ^a,b   Ralston, Stuart H ^b   Van't Hof, Rob J ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABD 295; BIPHENYLSULFONAMIDE; SULFONAMIDE;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUZUKI REACTION; TREATMENT OUTCOME;

ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OVARIECTOMY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33845496040     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051236m     Document Type: Article

References (29)

1. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 2000, 289, 1504-1508.
2. Seeman, E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359, 1841-1850.
3. Roodman, G. D.; Windle, J. J. Paget disease of bone. J. Clin. Invest. 2005, 115, 200-208.
4. Berenson, J. R.; Lipton, A. Use of bisphosphonates in patients with metastatic bone disease. Oncology (Williston Park) 1998, 12, 1573-1579.
5. Walsh, N. C.; Gravallese, E. M. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr. Opin. Rheumatol. 2004, 16, 419-427.
6. Rodan, G. A.; Martin, T. J. Therapeutic approaches to bone diseases. Science 2000, 289, 1508-1514.
7. Delmas, P. D. The use of bisphosphonates in the treatment of osteoporosis. Curr. Opin. Rheumatol. 2005, 17, 462-466.
8. Mehta, N. M.; Malootian, A.; Gilligan, J. P. Calcitonin for osteoporosis and bone pain. Curr. Pharm. Des. 2003, 9, 2659-2676.
9. Cummings, S. R.; Chapurlat, R. D. What PROOF proves about calcitonin and clinical trials. Am. J. Med. 2000, 109, 330-331.
10. Devogelaer, J. P. A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. Drug Saf. 1998, 19, 141-154.
11. Chase, J. L. Lowering the risk of esophagitis from alendronate therapy. Am. J. Health-Syst. Pharm. 1998, 55, 892-893.
12. Kelly, R.; Taggart, H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. Br. Med. J. 1997, 315, 1235.
13. Adami, S.; Bhalla, A. K.; Dorizzi, R.; Montesanti, F.; Rosini, S.; Salvagno, G.; Lo, C. V. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 1987, 41, 326-331.
14. Fuleihan, G. E. Tissue-specific estrogens. The promise for the future. N. Engl. J. Med. 1997, 337, 1686-1687.
15. Beral, V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362, 419-427.
16. Beral, V.; Bull, D.; Reeves, G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005, 365, 1543-1551.
17. Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 2002, 288, 321-333.
18. van't Hof, R. J.; Idris, A. I.; Ridge, S. A.; Dunford, J.; Greig, I. R.; Ralston, S. H. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J. Bone Miner. Res. 2004, 19, 1651-1660.
19. O'Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.; Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man, C. F.; Hallak, H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem. 2000, 43, 156-166.
20. Luckman, S. P.; Coxon, F. P.; Ebetino, F. H.; Russell, R. G.; Rogers, M. J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J. Bone Miner. Res. 1998, 13, 1668-1678.
21. King, F. D. Medicinal Chemistry; Royal Society of Chemistry: Cambridge, U.K., 2002.
22. Thomas, G. Medicinal Chemistry; John Wiley and Sons Ltd.: Chichester, U.K., 2000.
23. Craig, P. N. Interdependence between physical parameters and selection of substituent groups for correlation studies. J. Med. Chem. 1971, 14, 680-684.
24. Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44, 1841-1846.
25. Swain, C. G.; Lupton, E. C. Field and resonance components of substituent effects. J. Am. Chem. Soc. 1968, 90, 4328-4337.
26. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
27. van't Hof, R. J. Osteoclast formation in the mouse coculture assay. Methods Mol. Med. 2003, 80, 145-152.
28. Armour, K. J.; van't Hof, R. J.; Armour, K. E.; Torbergsen, A. C.; Del Soldato, P.; Ralston, S. H. Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Arthritis Rheum. 2001, 44, 2185-2192.
29. Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl aryl sulfonamides as therapeutic agents for the treatment of bone conditions. GB Patent WO2005118528, 2005.